肝细胞癌治疗新进展

周俭; 黄晓勇

doi:10.12449/JCH250801

肝细胞癌治疗新进展

DOI: 10.12449/JCH250801

周俭^, ,,
黄晓勇

复旦大学附属中山医院肝胆肿瘤与肝移植外科，上海 200032

基金项目:

国家自然科学基金 (82273234);

上海市自然科学基金 (21ZR1412200)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：黄晓勇负责撰写论文；周俭负责论文设计，指导文章撰写并最后定稿。

详细信息

通信作者:
周俭， zhou.jian@zs-hospital.sh.cn （ORCID： 0000-0002-2118-1117）

计量
- 文章访问数: 761
- HTML全文浏览量: 332
- PDF下载量: 480
- 被引次数: 0
出版历程
- 收稿日期: 2025-07-11
- 录用日期: 2025-07-26
- 出版日期: 2025-08-25

The latest advances in the treatment of hepatocellular carcinoma

Jian ZHOU^{,
,},
Xiaoyong HUANG

Department of Hepatobiliary Surgery and Liver Transplantation，Zhongshan Hospital，Fudan University，Shanghai 200032，China

More Information

Corresponding author: ZHOU Jian， zhou.jian@zs-hospital.sh.cn （ORCID： 0000-0002-2118-1117）

摘要

摘要: 肝细胞癌（HCC）是一种危害严重的世界性重大公共健康问题，其发病率和死亡率长期居高不下。世界卫生组织数据显示，2022年全球新发HCC病例86.6万例，死亡75.9万例，预计到2040年，HCC的新发和死亡病例将大幅增加。面对这一严峻挑战，近年来HCC诊疗取得了显著进展，从传统手术和局部治疗的优化，到靶向治疗和免疫治疗的突破性变革，再到精准医学理念的深入应用，为不同分期患者提供了更多的治疗选择和生存机会。本文旨在系统梳理HCC治疗进展，分析当前的治疗困境并展望未来发展方向，以期为临床实践和学术研究提供参考。
- 癌，肝细胞 /
- 肝切除术 /
- 分子靶向治疗 /
- 免疫疗法
Abstract: Hepatocellular carcinoma （HCC） is a severely detrimental global public health issue， and its incidence and mortality rates remain at a high level. According to the data from the World Health Organization， there were 866 000 new cases of HCC and 759 000 deaths worldwide in 2022， and it is predicted that by 2040， there will be significant increases in the numbers of new cases and deaths due to HCC. In the face of these great challenges， significant advances have been made in the diagnosis and treatment of HCC in recent years， and from the improvements in traditional surgeries and local treatment to groundbreaking innovations in targeted therapy and immunotherapy and the application of the concept of precision medicine， various treatment methods have provided more treatment options and survival opportunities for patients with different stages. This article reviews the advances in the treatment of HCC and analyzes current therapeutic difficulties and future development directions， in order to provide a reference for clinical practice and academic research.
- Carcinoma， Hepatocellular /
- Hepatectomy /
- Molecular Targeted Therapy /
- Immunotherapy

HTML全文

参考文献(36)

[1]	MORIS D, MARTININO A, SCHILTZ S, et al. Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians[J]. CA Cancer J Clin, 2025. DOI: 10.3322/caac.70018.[ Online ahead of print]
[2]	MUELLER S, MILLONIG G, SEITZ HK. Alcoholic liver disease and hepatitis C: A frequently underestimated combination[J]. World J Gastroenterol, 2009, 15( 28): 3462- 3471. DOI: 10.3748/wjg.15.3462.
[3]	YANG C, ZHANG HL, ZHANG LM, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2023, 20( 4): 203- 222. DOI: 10.1038/s41575-022-00704-9.
[4]	ORCUTT ST, ANAYA DA. Liver resection and surgical strategies for management of primary liver cancer[J]. Cancer Control, 2018, 25( 1): 1073274817744621. DOI: 10.1177/1073274817744621.
[5]	YIN L, LI H, LI AJ, et al. Partial hepatectomy vs transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: A RCT[J]. J Hepatol, 2014, 61( 1): 82- 88. DOI: 10.1016/j.jhep.2014.03.012.
[6]	WANG Z, PENG YF, HU JW, et al. Associating liver partition and portal vein ligation for staged hepatectomy for unresectable hepatitis B virus-related hepatocellular carcinoma: A single center study of 45 patients[J]. Ann Surg, 2020, 271( 3): 534- 541. DOI: 10.1097/SLA.0000000000-002942.
[7]	HUANG XY, DU W, ZHANG W, et al. Sequential hepatic artery infusion chemotherapy and transarterial chemoembolization combined with anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors and immune checkpoint inhibitors(quadruple therapy) as first-line therapy for advanced hepatocellular carcinoma: A single-center retrospective cohort study[J]. J Clin Oncol, 2025, 43( 16_suppl): e16180. DOI: 10.1200/jco.2025.43.16_suppl.e16180
[8]	AKULA V, CHEN L, ACIKGOZ Y, et al. Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma[J]. NPJ Precis Oncol, 2025, 9( 1): 60. DOI: 10.1038/s41698-025-00846-4.
[9]	QIN SK, CHEN MS, CHENG AL, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma(IMbrave050): A randomised, open-label, multicentre, phase 3 trial[J]. Lancet, 2023, 402( 10415): 1835- 1847. DOI: 10.1016/S0140-6736(23)01796-8.
[10]	PAVEL MC, FUSTER J. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions[J]. World J Gastroenterol, 2018, 24( 32): 3626- 3636. DOI: 10.3748/wjg.v24.i32.3626.
[11]	TONIUTTO P, FUMOLO E, FORNASIERE E, et al. Liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A comprehensive review[J]. J Clin Med, 2021, 10( 17): 3932. DOI: 10.3390/jcm10173932.
[12]	MEHTA N, FRENETTE C, TABRIZIAN P, et al. Downstaging outcomes for hepatocellular carcinoma: Results from the multicenter evaluation of reduction in tumor size before liver transplantation(MERITS-LT) consortium[J]. Gastroenterology, 2021, 161( 5): 1502- 1512. DOI: 10.1053/j.gastro.2021.07.033.
[13]	REZAEE-ZAVAREH MS, YEO YH, WANG TL, et al. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis[J]. J Hepatol, 2025, 82( 1): 107- 119. DOI: 10.1016/j.jhep.2024.06.042.
[14]	SHI GM, WANG JP, HUANG XW, et al. Graft programmed death ligand 1 expression as a marker for transplant rejection following anti-programmed death 1 immunotherapy for recurrent liver tumors[J]. Liver Transpl, 2021, 27( 3): 444- 449. DOI: 10.1002/lt.25887.
[15]	TAO KS, YANG ZX, ZHANG X, et al. Gene-modified pig-to-human liver xenotransplantation[J]. Nature, 2025, 641( 8064): 1029- 1036. DOI: 10.1038/s41586-025-08799-1.
[16]	LYU N, WANG X, LI JB, et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase III trial(FOHAIC-1)[J]. J Clin Oncol, 2022, 40( 5): 468- 480. DOI: 10.1200/JCO.21.01963.
[17]	SANGRO B, KUDO M, ERINJERI JP, et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma(EMERALD-1): A multiregional, randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet, 2025, 405( 10474): 216- 232. DOI: 10.1016/S0140-6736(24)02551-0.
[18]	KUDO M, REN ZG, GUO YB, et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma(LEAP-012): A multicentre, randomised, double-blind, phase 3 study[J]. Lancet, 2025, 405( 10474): 203- 215. DOI: 10.1016/S0140-6736(24)02575-3.
[19]	DAWSON LA, WINTER KA, KNOX JJ, et al. NRG/RTOG 1112: Randomized phase III study of sorafenib vs stereotactic body radiation therapy(SBRT) followed by sorafenib in hepatocellular carcinoma(HCC)[J]. J Clin Oncol, 2023, 41( 4_suppl): 489. DOI: 10.1200/jco.2023.41.4_suppl.489.
[20]	O’KANE GM, MESCI AM, CHEN EX, et al. Pembrolizumab and stereotactic radiotherapy combined in subjects with advanced HCC: A phase II study(PEMRAD)[J]. J Clin Oncol, 2025, 43( 4_suppl): 602. DOI: 10.1200/jco.2025.43.4_suppl.602.
[21]	LLOVET JM, RICCI S, MAZZAFERRO V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359( 4): 378- 390. DOI: 10.1056/nejmoa0708857.
[22]	KUDO M, FINN RS, QIN SK, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391( 10126): 1163- 1173. DOI: 10.1016/S0140-6736(18)30207-1.
[23]	KELLEY RK, RYOO BY, MERLE P, et al. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: A subgroup analysis of the phase 3 CELESTIAL trial[J]. ESMO Open, 2020, 5( 4): e000714. DOI: 10.1136/esmoopen-2020-000714.
[24]	ZHU AX, KANG YK, YEN CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations(REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20( 2): 282- 296. DOI: 10.1016/S1470-2045(18)30937-9.
[25]	YAU T, PARK JW, FINN RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma(CheckMate 459): A randomised, multicentre, open-label, phase 3 trial[J]. Lancet Oncol, 2022, 23( 1): 77- 90. DOI: 10.1016/S1470-2045(21)00604-5.
[26]	FINN RS, QIN SK, IKEDA M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382( 20): 1894- 1905. DOI: 10.1056/NEJMoa1915745.
[27]	GALLE PR, DECAENS T, KUDO M, et al. Nivolumab(NIVO) plus ipilimumab(IPI) vs lenvatinib(LEN) or sorafenib(SOR) as first-line treatment for unresectable hepatocellular carcinoma(uHCC): First results from CheckMate 9DW[J]. J Clin Oncol, 2024, 42( 17_suppl): LBA4008. DOI: 10.1200/jco.2024.42.17_suppl.lba4008.
[28]	REN ZG, XU JM, BAI YX, et al. Sintilimab plus a bevacizumab biosimilar(IBI₃05) versus sorafenib in unresectable hepatocellular carcinoma(ORIENT-32): A randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22( 7): 977- 990. DOI: 10.1016/S1470-2045(21)00252-7.
[29]	XU JM, ZHANG YQ, WANG G, et al. SCT-I10A combined with a bevacizumab biosimilar(SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A randomized phase 3 trial[J]. J Clin Oncol, 2024, 42( 16_suppl): 4092. DOI: 10.1200/jco.2024.42.16_suppl.4092.
[30]	QIN SK, CHAN SL, GU SZ, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma(CARES-310): A randomised, open-label, international phase 3 study[J]. Lancet, 2023, 402( 10408): 1133- 1146. DOI: 10.1016/S0140-6736(23)00961-3.
[31]	ZHOU J, BAI L, LUO J, et al. Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma(APOLLO): A randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2025, 26( 6): 719- 731. DOI: 10.1016/S1470-2045(25)00190-1.
[32]	FAN J, ZHOU J, HUANG XW, et al. Phase I study of Ori-C101, an armored GPC3-directed CAR-T, in patients with advanced hepatocellular carcinoma(HCC)[J]. J Clin Oncol, 2025, 43( 16_suppl): 4084. DOI: 10.1200/jco.2025.43.16_suppl.4084.
[33]	ZHU AX, ABBAS AR, de GALARRETA MR, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma[J]. Nat Med, 2022, 28( 8): 1599- 1611. DOI: 10.1038/s41591-022-01868-2.
[34]	FU SY, DEBES JD, BOONSTRA A. DNA methylation markers in the detection of hepatocellular carcinoma[J]. Eur J Cancer, 2023, 191: 112960. DOI: 10.1016/j.ejca.2023.112960.
[35]	BARTOLOMUCCI A, NOBREGA M, FERRIER T, et al. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology[J]. NPJ Precis Oncol, 2025, 9( 1): 84. DOI: 10.1038/s41698-025-00876-y.
[36]	YOU HY, WANG JF, MA RX, et al. Clinical interpretability of deep learning for predicting microvascular invasion in hepatocellular carcinoma by using attention mechanism[J]. Bioengineering(Basel), 2023, 10( 8): 948. DOI: 10.3390/bioengineering10080948.